Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics

Spasticity, characterized by elevated muscle tone, is commonly managed with botulinum toxin type A (BTX-A). However, BTX-A can paradoxically increase passive muscle forces, narrow muscles’ length range of force exertion (l<sub>range</sub>), and elevate extracellular matrix (ECM) stiffnes...

Full description

Saved in:
Bibliographic Details
Main Authors: Cemre Su Kaya Keles, Zeynep D. Akdeniz Dogan, Can A. Yucesoy
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Toxins
Subjects:
Online Access:https://www.mdpi.com/2072-6651/17/5/234
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850126810608566272
author Cemre Su Kaya Keles
Zeynep D. Akdeniz Dogan
Can A. Yucesoy
author_facet Cemre Su Kaya Keles
Zeynep D. Akdeniz Dogan
Can A. Yucesoy
author_sort Cemre Su Kaya Keles
collection DOAJ
description Spasticity, characterized by elevated muscle tone, is commonly managed with botulinum toxin type A (BTX-A). However, BTX-A can paradoxically increase passive muscle forces, narrow muscles’ length range of force exertion (l<sub>range</sub>), and elevate extracellular matrix (ECM) stiffness. C3 transferase, known to inhibit myofibroblast and fascial tissue contractility, may counteract ECM stiffening. This study investigated whether combining BTX-A with C3 transferase reduces active forces without altering passive forces or l<sub>range</sub>. Additionally, we examined the isolated effects of C3 transferase on muscle levels. Male Wistar rats received injections into the tibialis anterior (TA): Control (<i>n</i> = 7, saline) and C3 + BTX-A (<i>n</i> = 7, 2.5 µg C3 + 0.1U BTX-A). TA forces were measured one month post-injection, and isolated C3 transferase effects were assessed in separate groups (Control and C3, <i>n</i> = 6 each). Active forces were 43.5% lower in the C3 + BTX-A group compared to the Control group. No differences between groups in passive forces (<i>p</i> = 0.33) or l<sub>range</sub> (<i>p</i> = 0.19) were observed. C3 transferase alone had no significant effect on relative muscle mass (<i>p</i> = 0.298) or collagen content (<i>p</i> = 0.093). Supplementing BTX-A with C3 transferase eliminates BTX-A’s adverse effects at the muscle level. C3 transferase alone causes no atrophy or collagen increase, which are key factors in BTX-A-induced ECM stiffening. This novel neurodenervant formula shows promise for advancing spasticity management.
format Article
id doaj-art-6c7b05af0cec4794a948db2d0992a202
institution OA Journals
issn 2072-6651
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Toxins
spelling doaj-art-6c7b05af0cec4794a948db2d0992a2022025-08-20T02:33:51ZengMDPI AGToxins2072-66512025-05-0117523410.3390/toxins17050234Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle MechanicsCemre Su Kaya Keles0Zeynep D. Akdeniz Dogan1Can A. Yucesoy2Institute of Biomedical Engineering, Boğaziçi University, 34684 Istanbul, TurkeyDepartment of Plastic, Reconstructive, and Aesthetic Surgery, Marmara University, 34854 Istanbul, TurkeyInstitute of Biomedical Engineering, Boğaziçi University, 34684 Istanbul, TurkeySpasticity, characterized by elevated muscle tone, is commonly managed with botulinum toxin type A (BTX-A). However, BTX-A can paradoxically increase passive muscle forces, narrow muscles’ length range of force exertion (l<sub>range</sub>), and elevate extracellular matrix (ECM) stiffness. C3 transferase, known to inhibit myofibroblast and fascial tissue contractility, may counteract ECM stiffening. This study investigated whether combining BTX-A with C3 transferase reduces active forces without altering passive forces or l<sub>range</sub>. Additionally, we examined the isolated effects of C3 transferase on muscle levels. Male Wistar rats received injections into the tibialis anterior (TA): Control (<i>n</i> = 7, saline) and C3 + BTX-A (<i>n</i> = 7, 2.5 µg C3 + 0.1U BTX-A). TA forces were measured one month post-injection, and isolated C3 transferase effects were assessed in separate groups (Control and C3, <i>n</i> = 6 each). Active forces were 43.5% lower in the C3 + BTX-A group compared to the Control group. No differences between groups in passive forces (<i>p</i> = 0.33) or l<sub>range</sub> (<i>p</i> = 0.19) were observed. C3 transferase alone had no significant effect on relative muscle mass (<i>p</i> = 0.298) or collagen content (<i>p</i> = 0.093). Supplementing BTX-A with C3 transferase eliminates BTX-A’s adverse effects at the muscle level. C3 transferase alone causes no atrophy or collagen increase, which are key factors in BTX-A-induced ECM stiffening. This novel neurodenervant formula shows promise for advancing spasticity management.https://www.mdpi.com/2072-6651/17/5/234botulinum toxin type AC3 transferasespasticity managementmuscle forcerange of motionextracellular matrix stiffness
spellingShingle Cemre Su Kaya Keles
Zeynep D. Akdeniz Dogan
Can A. Yucesoy
Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics
Toxins
botulinum toxin type A
C3 transferase
spasticity management
muscle force
range of motion
extracellular matrix stiffness
title Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics
title_full Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics
title_fullStr Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics
title_full_unstemmed Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics
title_short Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics
title_sort development and preclinical testing of a novel neurodenervant in the rat c3 transferase mitigates botulinum toxin s adverse effects on muscle mechanics
topic botulinum toxin type A
C3 transferase
spasticity management
muscle force
range of motion
extracellular matrix stiffness
url https://www.mdpi.com/2072-6651/17/5/234
work_keys_str_mv AT cemresukayakeles developmentandpreclinicaltestingofanovelneurodenervantintheratc3transferasemitigatesbotulinumtoxinsadverseeffectsonmusclemechanics
AT zeynepdakdenizdogan developmentandpreclinicaltestingofanovelneurodenervantintheratc3transferasemitigatesbotulinumtoxinsadverseeffectsonmusclemechanics
AT canayucesoy developmentandpreclinicaltestingofanovelneurodenervantintheratc3transferasemitigatesbotulinumtoxinsadverseeffectsonmusclemechanics